NVNO Strangle Strategy
NVNO (enVVeno Medical Corporation), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
NVNO (enVVeno Medical Corporation) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $155,953, a beta of 1.09 versus the broader market, a 52-week range of 8.67-196.7, average daily share volume of 14K, a public-listing history dating back to 2018, approximately 37 full-time employees. These structural characteristics shape how NVNO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.09 places NVNO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on NVNO?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current NVNO snapshot
As of May 15, 2026, spot at $9.30, ATM IV 68.00%, IV rank 10.52%, expected move 19.50%. The strangle on NVNO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 98-day expiry.
Why this strangle structure on NVNO specifically: NVNO IV at 68.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a NVNO strangle, with a market-implied 1-standard-deviation move of approximately 19.50% (roughly $1.81 on the underlying). The 98-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NVNO expiries trade a higher absolute premium for lower per-day decay. Position sizing on NVNO should anchor to the underlying notional of $9.30 per share and to the trader's directional view on NVNO stock.
NVNO strangle setup
The NVNO strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NVNO near $9.30, the first option leg uses a $9.77 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NVNO chain at a 98-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NVNO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $9.77 | N/A |
| Buy 1 | Put | $8.84 | N/A |
NVNO strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
NVNO strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on NVNO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on NVNO
Strangles on NVNO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NVNO chain.
NVNO thesis for this strangle
The market-implied 1-standard-deviation range for NVNO extends from approximately $7.49 on the downside to $11.11 on the upside. A NVNO long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current NVNO IV rank near 10.52% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NVNO at 68.00%. As a Healthcare name, NVNO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NVNO-specific events.
NVNO strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NVNO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NVNO alongside the broader basket even when NVNO-specific fundamentals are unchanged. Always rebuild the position from current NVNO chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on NVNO?
- A strangle on NVNO is the strangle strategy applied to NVNO (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With NVNO stock trading near $9.30, the strikes shown on this page are snapped to the nearest listed NVNO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are NVNO strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the NVNO strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 68.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NVNO strangle?
- The breakeven for the NVNO strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NVNO market-implied 1-standard-deviation expected move is approximately 19.50%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on NVNO?
- Strangles on NVNO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NVNO chain.
- How does current NVNO implied volatility affect this strangle?
- NVNO ATM IV is at 68.00% with IV rank near 10.52%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.